Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Sex-linked Disorders01:43

Sex-linked Disorders

101.8K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
101.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

146
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
146
Lethal Alleles02:41

Lethal Alleles

15.4K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
15.4K
X-linked Traits01:19

X-linked Traits

54.4K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
54.4K
Pedigree Analysis01:35

Pedigree Analysis

84.1K
Overview
84.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.

Journal of the Endocrine Society·2026
Same author

Continuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment.

European journal of endocrinology·2026
Same author

Excluding children: What "no-kids zones" reveal about our collective future.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study.

The lancet. Diabetes & endocrinology·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026
Same author

Characterisation of Urine-Derived Cells for the Molecular Diagnosis of Rare Disorders.

International journal of molecular sciences·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 15, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.4K

Hipofosfatemia ligada al X

Peter Kamenický1, Karine Briot2, Craig F Munns3

  • 1Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Le Kremlin-Bicêtre, France; Centre de Référence des Maladies du Métabolisme du Calcium et du Phosphate, Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.

Lancet (London, England)
|August 24, 2024
PubMed
Resumen
Este resumen es generado por máquina.

La hipofosfatemia ligada al X, un trastorno genético de los defectos del gen PHEX, causa niveles bajos de fosfato debido al exceso de FGF23. La orientación de FGF23 mejora los resultados, pero se necesitan cuidados de por vida y nuevos tratamientos como la reparación genética.

Más Videos Relacionados

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.3K

Videos de Experimentos Relacionados

Last Updated: Jun 15, 2025

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.4K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K
Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.3K

Área de la Ciencia:

  • Genética y Biología Molecular
  • Endocrinología
  • Enfermedad ósea metabólica

Sus antecedentes:

  • La hipofosfatemia ligada a X (XLH) es un trastorno genético causado por mutaciones en el gen homólogo de la endopeptidasa reguladora de fosfato ligada a X (PHEX).
  • La deficiencia de PHEX conduce a niveles elevados del factor de crecimiento de los fibroblastos 23 (FGF23), una hormona fosfatúrica.
  • Los niveles elevados de FGF23 causan pérdida de fosfato renal y deterioro de la síntesis de calcitriol, lo que resulta en hipofosfatemia y mineralización ósea defectuosa.

Objetivo del estudio:

  • Revisar el conocimiento actual de la hipofosfatemia ligada al X.
  • Para discutir la fisiopatología que involucra los defectos del gen PHEX y FGF23.
  • Para resaltar los avances terapéuticos recientes y las direcciones futuras en el manejo de XLH.

Principales métodos:

  • Revisión de la literatura de estudios genéticos, moleculares y clínicos sobre la hipofosfatemia ligada al X.
  • Análisis del papel de las mutaciones del gen PHEX y FGF23 en la patogénesis de la enfermedad.
  • Evaluación de las estrategias de tratamiento actuales y emergentes dirigidas a FGF23 y PHEX.

Principales resultados:

  • Los defectos del gen PHEX son la causa principal de XLH, lo que lleva a un aumento de la producción de FGF23.
  • El FGF23 elevado interrumpe la homeostasis del fosfato y la mineralización ósea, causando manifestaciones características de la enfermedad.
  • La orientación al FGF23 ha mostrado mejoras significativas en los resultados de los pacientes.

Conclusiones:

  • La hipofosfatemia ligada al X es un trastorno genético complejo con una morbilidad significativa.
  • Las estrategias terapéuticas dirigidas a FGF23 han avanzado en el manejo de la enfermedad.
  • Los enfoques innovadores, incluida la reparación del gen PHEX, son cruciales para reducir aún más la carga de la enfermedad y mejorar la atención de por vida.